A team of specialists from the University of Navarra Clinic has initiated a new clinical trial to curb the cognitive deterioration caused by Alzheimer's disease. This is a multicentric, recruitment-based investigation involving U.S. and European centers. Currently, about 600,000 people in Spain suffer from this disease.
The current treatment is aimed at people with a slight cognitive impairment, ie in the most incipient stages in which the disease still does not affect the day to day of the sick. However, this new drug (Crenezumab) also includes people with mild-stage dementia, that is, in those stages in which the patient begins to have problems in carrying out their daily activities.
As explained by Dr. Mario Riverol, neurologist at the University of Navarra Clinic, specializing in Alzheimer's disease and principal investigator in this essay: "These are antibodies that act on amyloid protein, which is deposited in the brain of the Alzheimer's, the main cause of the disease. The function of the drug is to "clean up" amyloid from the brain, in order to stop the evolution of the disease. "
The Alzheimer, which currently does not have a cure although there is treatment to lessen some symptoms, involves loss of memory, confusion and change of personality. Around the world more than 47 million people suffer from dementia, of which Alzheimer's disease is the most common form.
The Alzheimer, which currently does not have a cure although there is treatment to lessen some symptoms, involves loss of memory, confusion and change of personality. Around the world more than 47 million people suffer from dementia, of which Alzheimer's disease is the most common form.
Cap comentari:
Publica un comentari a l'entrada